Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome

The goal of this clinical trial is to learn if Stapokibart (CM310) works to treat Non-Allergic Rhinitis with Eosinophilia Syndrome (NARES) in adults. It will also learn about the safety of CM310. The main questions it aims to answer are: Does drug CM310 relieve the symptoms of participants? What medical problems do participants have when injecting CM310? Researchers will compare CM310 to a placebo (a look-alike substance that contains no drug) to see if CM310 works to treat NARES. Participants will: Inject CM310 or a placebo every 2 weeks for 12 weeks, and follow up for another 8 weeks. Visit the clinic once every 2 weeks for checkups and tests. Keep a diary of their symptoms every day.

NCT Number	NCT07240376
Lead Sponsor	Huazhong University of Science and Technology Collaborators: Renmin Hospital of Wuhan University, Wuhan TongJi Hospital
Conditions	Non-Allergic Rhinitis With Eosinophilia Syndrome
Enrollment	90 participants
Start Date	2025-11-25
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-02-28 (estimated)
Updated on ClinicalTrials.gov	2025-11-20